Two Sigma Investments LP Takes Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Two Sigma Investments LP bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 200,797 shares of the company's stock, valued at approximately $66,000. Two Sigma Investments LP owned approximately 10.74% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after buying an additional 1,855,907 shares during the period. Jane Street Group LLC grew its position in shares of Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after buying an additional 1,635,119 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $526,000. Northern Trust Corp acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $162,000. Finally, Commonwealth Equity Services LLC acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $40,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Analysts Set New Price Targets

TNXP has been the subject of several recent research reports. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, June 3rd. Noble Financial reiterated an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. Finally, Wall Street Zen raised shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.

Tonix Pharmaceuticals Trading Down 7.4%

TNXP stock traded down $2.56 during mid-day trading on Friday, reaching $31.98. 680,544 shares of the stock traded hands, compared to its average volume of 922,491. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $6.76 and a 52-week high of $137.25. The company has a market cap of $234.25 million, a P/E ratio of -0.01 and a beta of 2.09. The stock's fifty day moving average is $25.07 and its 200-day moving average is $23.59.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman acquired 4,000 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the transaction, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. The trade was a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.03% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.